Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Children who are deaf or hard of hearing in inclusive educational settings: a literature review on interactions with peers.

Xie YH, Potměšil M, Peters B.

J Deaf Stud Deaf Educ. 2014 Oct;19(4):423-37. doi: 10.1093/deafed/enu017. Epub 2014 Jul 21. Review.

PMID:
25052819
2.

Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.

Cohen DJ, Newman E, Iqbal S, Chang RY, Potmesil M, Ryan T, Donahue B, Chandra A, Liu M, Utate M, Hiotis S, Pachter LH, Hochster H, Muggia F.

Ann Surg Oncol. 2012 Feb;19(2):478-85. doi: 10.1245/s10434-011-1940-8. Epub 2011 Jul 19.

PMID:
21769462
3.

Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.

Newman E, Potmesil M, Ryan T, Marcus S, Hiotis S, Yee H, Norwood B, Wendell M, Muggia F, Hochster H.

Semin Oncol. 2005 Dec;32(6 Suppl 9):S97-100.

PMID:
16399443
4.

Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.

Marcus SG, Cohen D, Lin K, Wong K, Thompson S, Rothberger A, Potmesil M, Hiotis S, Newman E.

J Gastrointest Surg. 2003 Dec;7(8):1015-22; discussion 1023.

PMID:
14675711
5.

Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.

Muggia FM, Liebes L, Hazarika M, Wadler S, Hamilton A, Hornreich G, Sorich J, Chiang C, Newman E, Potmesil M, Hochster H.

Anticancer Drugs. 2002 Sep;13(8):819-25.

PMID:
12394266
6.

Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.

Newman E, Marcus SG, Potmesil M, Sewak S, Yee H, Sorich J, Hayek M, Muggia F, Hochster H.

J Gastrointest Surg. 2002 Mar-Apr;6(2):212-23; discussion 223.

PMID:
11992807
7.

Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin.

Muggia F, Liebes L, Potmesil M, Hamilton A, Hochster H, Hornreich G, Sorich J, Downey A, Wasserstrom H.

Ann N Y Acad Sci. 2000;922:178-87. Review.

PMID:
11193893
8.

Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.

O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M.

Clin Cancer Res. 1999 Jan;5(1):181-7.

9.

Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.

Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, Cho J, Adler H, Dar K, Zeleniuch-Jacquotte A, Hochster H.

Clin Cancer Res. 1998 Mar;4(3):545-57.

10.

9-Aminocamptothecin and beyond. Preclinical and clinical studies.

Potmesil M, Arbuck SG, Takimoto CH, Liebes L, Hochster H.

Ann N Y Acad Sci. 1996 Dec 13;803:231-46. Review. No abstract available.

PMID:
8993517
11.

Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.

Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW.

Oncogene. 1996 Mar 7;12(5):1055-62.

PMID:
8649796
12.

Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models.

Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC.

Cancer Res. 1995 Dec 1;55(23):5637-41.

13.

Clonal analysis of IgM+ CD5+ CLL B cells.

Schettino EW, Newcomb EW, Potmesil M, Inghirami G, Casali P.

Ann N Y Acad Sci. 1995 Sep 29;764:485-91. No abstract available.

PMID:
7486572
14.
15.

Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.

Silber R, Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR, Morse L, Drygas JC, Canellakis ZN, Potmesil M.

Blood. 1994 Nov 15;84(10):3440-6.

16.

Camptothecins: from bench research to hospital wards.

Potmesil M.

Cancer Res. 1994 Mar 15;54(6):1431-9. Review. No abstract available.

17.

Preclinical and clinical development of camptothecins.

Costin D, Potmesil M.

Adv Pharmacol. 1994;29B:51-72. Review. No abstract available.

PMID:
8996601
18.

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW.

Blood. 1993 Dec 1;82(11):3452-9.

19.

Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells.

Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF.

Cancer Res. 1991 Nov 15;51(22):6039-44.

20.

Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.

Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS Jr, Silber R, Potmesil M.

Cancer Res. 1991 Jun 1;51(11):3052-5.

21.

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M.

Science. 1989 Nov 24;246(4933):1046-8.

PMID:
2555920
22.

DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.

Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M.

Cancer Res. 1989 Nov 1;49(21):5969-78.

23.

Lack of drug-induced DNA cross-links in chlorambucil-resistant Chinese hamster ovary cells.

Jiang BZ, Bank BB, Hsiang YH, Shen T, Potmesil M, Silber R.

Cancer Res. 1989 Oct 15;49(20):5514-7.

24.

DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.

Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M.

Cancer Res. 1989 Aug 15;49(16):4385-9. Erratum in: Cancer Res 1989 Dec 1;49(23):6868.

25.

Studies on drug resistance in chronic lymphocytic leukemia.

Silber R, Potmesil M, Bank BB.

Adv Enzyme Regul. 1989;29:267-76.

PMID:
2561248
26.

Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.

Potmesil M, Hsiang YH, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenza TJ, Penziner A, Kanganis D, et al.

Cancer Res. 1988 Jun 15;48(12):3537-43. Erratum in: Cancer Res 1988 Aug 15;48(16):4716. Forlenzar TJ [corrected to Forlenza TJ].

27.

Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II.

Silber R, Liu LF, Israel M, Bodley AL, Hsiang YH, Kirschenbaum S, Sweatman TW, Seshadri R, Potmesil M.

NCI Monogr. 1987;(4):111-5.

PMID:
3041237
28.

DNA topoisomerase II as a potential factor in drug resistance of human malignancies.

Potmesil M, Hsiang YH, Liu LF, Wu HY, Traganos F, Bank B, Silber R.

NCI Monogr. 1987;(4):105-9.

PMID:
3041236
29.

Effects of N-trifluoroacetyladriamycin-14-O-hemiadipate and radiation on L1210 cells.

Potmesil M, Israel M, Kirschenbaum S, Bowen J, Silber R.

Radiat Res. 1986 Feb;105(2):147-57.

PMID:
3754052
30.

Effects of new N-alkyl analogues of adriamycin on in vitro survival and cell cycle progression of L1210 cells.

Traganos F, Israel M, Silber R, Seshadri R, Kirschenbaum S, Potmesil M.

Cancer Res. 1985 Dec;45(12 Pt 1):6273-9.

31.

Two mechanisms of adriamycin-DNA interaction in L1210 cells.

Potmesil M, Israel M, Silber R.

Biochem Pharmacol. 1984 Oct 15;33(20):3137-42.

PMID:
6487364
32.

Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells.

Potmesil M, Kirschenbaum S, Israel M, Levin M, Khetarpal VK, Silber R.

Cancer Res. 1983 Aug;43(8):3528-33.

33.

In vivo effects of adriamycin or N-trifluoroacetyladriamycin-14-valerate on a mouse lymphoma.

Potmesil M, Levin M, Traganos F, Israel M, Darzynkiewicz Z, Khetarpal VK, Silber R.

Eur J Cancer Clin Oncol. 1983 Jan;19(1):109-22. No abstract available.

PMID:
6602051
34.

Adriamycin damage: in vivo repair by lymphoma cells.

Potmesil M, Levin M, Goldfeder A, Silber R.

J Natl Cancer Inst. 1981 Dec;67(6):1259-63.

PMID:
6947109
35.

Protein-associated DNA breaks and DNA-protein cross-links caused by DNA nonbinding derivatives of adriamycin in L1210 cells.

Levin M, Silber R, Israel M, Goldfeder A, Khetarpal VK, Potmesil M.

Cancer Res. 1981 Mar;41(3):1006-10.

36.
37.
38.
39.

Nucleolar morphology and cell proliferation kinetics of thymic lymphocytes.

Potmesil M, Goldfeder A.

Exp Cell Res. 1973 Mar 15;77(1):31-40. No abstract available.

PMID:
4570354
40.

Nucleolar morphology and maturation of thymic lymphocytes.

Potmesil M, Goldfeder A.

J Cell Biol. 1972 Jun;53(3):832-7. No abstract available.

41.

Inhibitory effect of polyinosinic:polycytidylic acid on the growth of transplantable mouse mammary carcinoma.

Potmesil M, Goldfeder A.

Proc Soc Exp Biol Med. 1972 Apr;139(4):1392-7. No abstract available.

PMID:
5023340
42.

Nucleolar morphology, nucleic acid syntheses, and growth rates of experimental tumors.

Potmesil M, Goldfeder A.

Cancer Res. 1971 Jun;31(6):789-97. No abstract available.

43.
44.

A further contribution on the incidence of ring shaped nucleoli and micronucleoli in mature human lymphocytes.

Smetana K, Potmĕsil M.

Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;93(1):16-23. No abstract available.

PMID:
4193295
46.

Significance of ring shaped nucleoli and micronucleoli in human lymphocytes.

Potmĕsil M, Smetana K.

Folia Biol (Praha). 1969;15(4):300-5. No abstract available.

PMID:
5802888
47.

A further contribution to the demonstration of RNA and nucleoli of blood cells in smear preparations.

Smetana K, Lejnar J, Potmĕsil M.

Folia Haematol Int Mag Klin Morphol Blutforsch. 1969;91(4):381-94. No abstract available.

PMID:
4184463
48.

The effect of chromomycin A3 on the formation of ring shaped nucleoli and incorporation of H3 uridine in cell cultures.

Potmĕsil M, Smetana K.

Folia Biol (Praha). 1968;14(2):132-9. No abstract available.

PMID:
5654698
49.

Ring shaped nucleoli in liver cells of rats after treatment with actinomycin D.

Smetana K, Potmĕsil M.

Z Zellforsch Mikrosk Anat. 1968;92(1):62-9. No abstract available.

PMID:
4884647
50.

A contribution to the demonstration of nucleoli and their nucleolar coefficient in the mature monocytes of human peripheral blood.

Smetana K, Potmĕsil M.

Folia Morphol (Praha). 1967;15(1):98-103. No abstract available.

PMID:
6036031

Supplemental Content

Loading ...
Support Center